Genetic Data Privacy

23andMe Bankruptcy Fuels DNA Privacy Fears as Millions’ Genetic Data Faces Sale

23andMe’s Chapter 11 bankruptcy filing has ignited serious privacy concerns, as the genetic data of millions of users is now a potential asset in the company’s sale. This sensitive information, used to predict disease predisposition and connect relatives, lacks robust federal protection under current U.S. law, unlike medical data held by healthcare providers. Experts warn of the potentially catastrophic consequences of data misuse by future owners, highlighting the irreplaceable nature of DNA and the limited recourse for individuals. The sale underscores the vulnerability of personal genetic information and the need for stronger data privacy regulations.

Read More

23andMe Files for Bankruptcy: User Data’s Uncertain Future

Facing financial difficulties and a £4.59 million fine from the UK’s ICO for a 2023 data breach, 23andMe has filed for bankruptcy protection. Co-founder and CEO Anne Wojcicki has resigned, with the company now seeking a buyer under court supervision. While 23andMe assures customers that data remains secure, the California Attorney General advises users to delete their information. The company, once valued at $6 billion, has struggled to maintain profitability since its 2021 IPO and ultimately failed to successfully pivot its business model.

Read More